ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,659 SEK | +0.20% |
|
+8.97% | +22.53% |
| Sales 2024 * | 51.18B 561B | Sales 2025 * | 54.76B 600B | Capitalization | 234B 2,563B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.52B 93.35B | Net income 2025 * | 10.2B 112B | EV / Sales 2024 * | 4.96 x |
| Net Debt 2024 * | 19.9B 218B | Net Debt 2025 * | 13.44B 147B | EV / Sales 2025 * | 4.52 x |
| P/E ratio 2024 * |
27.8
x | P/E ratio 2025 * |
23.2
x | Employees | 89,900 |
| Yield 2024 * |
2.06% | Yield 2025 * |
2.15% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
| 1 day | +0.20% | ||
| 1 week | +8.97% | ||
| Current month | +14.18% | ||
| 1 month | +15.21% | ||
| 3 months | +18.38% | ||
| 6 months | +18.34% | ||
| Current year | +22.53% |
1 week
1 526.00
1 695.00
1 month
1 416.501 695.00
Current year
1 261.001 695.00
1 year
1 261.001 695.00
3 years
889.501 695.00
5 years
700.001 695.00
10 years
447.501 695.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 63 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 1,658 | +0.18% | 37 334 |
| 24-04-29 | 1,656 | +0.58% | 292,246 |
| 24-04-26 | 1,646 | +0.27% | 316,442 |
| 24-04-25 | 1,642 | +6.35% | 917,143 |
| 24-04-24 | 1,544 | +1.41% | 341,079 |
Delayed Quote Nasdaq Stockholm, April 30, 2024 at 04:16 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-04-29
- Roadshow - Day 2
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
150.9
USD
Average target price
164.3
USD
Spread / Average Target
+8.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.47% | 664B | |
| +25.70% | 567B | |
| -6.33% | 354B | |
| +19.35% | 330B | |
| +4.23% | 286B | |
| +4.71% | 199B | |
| -10.10% | 196B | |
| -4.04% | 148B | |
| -10.94% | 145B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock
